Saturday (22.10.2022) Sunday (23.10.2022) Monday (24.10.2022)
 
Großer Saal


Interactive Case Discussion

  • T. Illidge
  • J. Zijlstra
  1. Case presentation: Greyzone Lymphoma

    • L. Pinczés
  2. Case presentation: Anti-PD1 Failure

    • G. Collins
  3. Case presentation: COVID19 immunity in lymphoma

    • S. Mellinghoff
  4. Case presentation: Primary progressive HL

    • A. Jacob
Großer Saal


Advanced Stages

  • O. Casasnovas
  • J. Radford
  1. Why I recommend BV-AVD

    • R. Advani
  2. Why I recommend PET-guided ABVD

    • A. Fosså
  3. Why I recommend PET-adapted escalated BEACOPP

    • P. Borchmann
  4. Discussion forum: Challenging standard recommendations from a patient's, nurse's and physician's perspective

    • M. Dreyling
    • J. Richardson
    • S. Wells
  5. WS Report: Learning through International Collaboration

    • P. Borchmann
    • A. Moskowitz
  6. FDG-PET and serum TARC levels after one cycle of BV-AVD in advanced stage Hodgkin lymphoma patients: results from the very early PET-response adapted EORTC-COBRA trial

    • W. Plattel
  7. Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group

    • P. Borchmann


Seminars and Workshops (parallel sessions)

  1. Seminar: Living beyond Lymphoma

    • L. Specht
    • F. van Leeuwen
  2. Workshop: The HL Microenvironment

    • S. Rodig
    • A. Rosenwald
  3. Workshop: PET beyond Deauville

    • S. Barrington
    • M. Hutchings
    • C. Kobe
  4. Workshop: Innovation for Older Patients

    • P. Bröckelmann
    • A. Fosså
  5. Joint EHA-ISHL Symposium

    • P. Borchmann
    • M. Dreyling
Coffee Break
Coffee Break
Großer Saal


Emerging Cellular Therapies – a Role in HL?

  • S. Ansell
  • P. Borchmann
  1. Clinical experience with Cellular Therapy in cH

    • B. Savoldo
  2. Design and manufacturing of CD30 CARs for cHL

    • C. Quintarelli
  3. Emerging indications for cellular therapy

    • P. Borchmann
Großer Saal


Special Situations in HL

  • R. Hoppe
  • M. Kersten
  1. HL in Pregnancy

    • D. Dierickx
  2. HIV-positive HL

    • O. Baiocchi
  3. alloSCT in the era of anti-PD1

    • A. Sureda
Coffee Break
Coffee Break
Coffee Break


Seminars and Workshops (parallel sessions)

  1. Seminar: Radiotherapy: Identifying the Beneficiaries

    • C. Baues
    • J. Yahalom
  2. Workshop: Bringing Liquid Biopsy to Patients

    • S. Borchmann
    • D. Rossi
  3. Seminar: Learning from Pediatric HL

    • J. Friedberg
    • C. Mauz-Körholz
  4. Workshop: NLPHL

    • M. Binkley
    • D. Eichenauer
    • S. Hartmann
Großer Saal


Living beyond Lymphoma

  • J. Radford
  • F. van Leeuwen
  1. Towards Lung Cancer Screening in Hodgkin Lymphoma Survivors

    • K. Linton
  2. GHSG data on fertility, fatigue and social reintegration and the ongoing EMBrACe study

    • K. Behringer
  3. WS Report: Living beyond Lymphoma

    • L. Specht
    • F. van Leeuwen
  4. Doxorubicin exposure and breast cancer risk in adolescent and adult Hodgkin lymphoma survivors

    • S. Neppelenbroek
  5. Reproduction patterns among Classical Hodgkin Lymphoma Survivors Treated with BEACOPP and ABVD in Sweden, Denmark, and Norway

    • J. Entrop
  6. Treatment and sex-specific exposure-based risk-stratification for care of survivors of childhood Hodgkin Lymphoma: A report from the Childhood Cancer Survivor Study.

    • M. Dinan
Großer Saal


Genomics, Biology and Microenvironment

  • W. Klapper
  • R. Küppers
  1. Biological Classification of HL by Liquid Biopsy

    • S. Borchmann
  2. Single Cell Transcriptomics of HL

    • C. Steidl
  3. WS Report: Bringing Liquid Biopsy to Patients

    • S. Borchmann
    • D. Rossi
  4. Characterization of cancer-associated fibroblasts in classical Hodgkin lymphoma

    • K. Karihtala
  5. High serum levels of Thymus and Activation Related Chemokine (TARC) precede Hodgkin lymphoma diagnosis by several years

    • A. Diepstra
  6. Single-cell RNA sequencing reveals the interplay between circulating CD4 T cells, B cells and cancer-associated monocytes in classic Hodgkin lymphoma treated with PD-1 blockade

    • J. Paczkowska
Coffee Break
Coffee Break
Coffee Break
Großer Saal


Opening paths to the next chapters of lymphoma treatmen

by Beigene
  1. In memoriam of Saul Rosenberg

    • R. Advani
  2. Welcome and Introduction to the topic

    • P. Borchmann
  3. Hodgkin’s lymphoma as a model for immuno-oncologic therapeutic approaches to lymphoma

    • P. Bröckelmann
  4. The challenge of the older patient in lymphoma therapy

    • G. Collins
  5. New trends in lymphoma therapy: future role of BTKi / CAR-T / bispecific antibodies

    • P. Zinzani
 
Großer Saal


Bridging the gap between efficacy and toxicity in the frontline treatment of stage IV Hodgkin lymphoma

by Takeda
  • G. Collins
  • A. Herrera
  • P. Zinzani
  1. Welcome and introduction

    • G. Collins
  2. Hot off the press: The latest data for the frontline treatment of patients with Stage IV CD30+ Hodgkin Lymphoma from ECHELON-1

    • G. Collins
  3. Bridging the gap: Balancing efficacy and toxicity in three challenging case studies (A debate and audience discussion with our panel)

    • G. Collins
    • A. Herrera
    • P. Zinzani
  4. Audience Q&A

  5. Summary and close

    • G. Collins
Großer Saal


Checkpoint Inhibition in Hodgkin Lymphoma – State of the art and future perspectives

by MSD
  • P. Borchmann
  1. Firstline therapy of classical Hodgkin Lymphoma – How can immunotherapy improve outcome?

    • P. Borchmann
  2. The current role of PD-1 inhibition in the treatment of relapsed or refractory classical Hodgkin Lymphoma

    • B. von Tresckow
  3. Strategies to enhance checkpoint inhibition

    • P. Bröckelmann
 
Coffee Break
Coffee Break
Coffee Break
Großer Saal


Early Stages

  • M. André
  • H. Eich
  1. Standard treatment of early-stage HL

    • J. Radford
  2. Individual risk assessment of RT in HL

    • R. Hoppe
  3. WS Report: NLPHL

    • M. Binkley
    • D. Eichenauer
    • S. Hartmann
  4. Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies

    • D. Eichenauer
  5. Radiation-Free Therapy as the INitial treatment of Good-prognosis early non-bulky Hodgkin lymphoma, defined by a low Metabolic Tumor Volume and a negative PET-2 - RAFTING Trial.

    • A. Gallamini
  6. Sharing decisions regarding radiotherapy for Hodgkin lymphoma: a qualitative study of the experiences of patients and clinicians in the UK

    • R. Shakir
Großer Saal


Older and Frail Patients

  • R. Cordoba Mascuñano
  • A. Evens
  1. Managing an Older Lymphoma Patient

    • R. Cordoba Mascuñano
  2. Treatment Strategies in Older HL Patients

    • A. Evens
  3. Workshop Report: Innovation for Older patients

    • P. Bröckelmann
    • A. Fosså
  4. AVD - a possible golden standard in the first-line treatment of older classical Hodgkin lymphoma patients.

    • N. Övergaard
  5. The Effect of Heart Failure on Management and Outcomes of Older Patients with Hodgkin Lymphoma

    • J. Upshaw
  6. Treatment patterns and outcomes for Hodgkin's Lymphoma (HL) patients (pts) aged 60 and older: a report from the Brazilian Prospective Hodgkin’s lymphoma Registry

    • I. Buvat
Großer Saal


Relapsed / Refractory HL

  • R. Advani
  • C. Moskowitz
  1. 1ˢᵗ Relapse of HL

    • C. Moskowitz
  2. Novel developments in R/R HL

    • G. Collins
  3. WS Report: PET beyond Deauville

    • S. Barrington
    • M. Hutchings
    • C. Kobe
  4. Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial.

    • A. Sureda
  5. High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma

    • A. Moskowitz
  6. Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I)

    • C. Diefenbach
Coffee Break
Coffee Break
Großer Saal


Closing Remarks

  1. Conference Highlights

    • R. Advani
Großer Saal


CAR T cell therapy in B Cell NHL: Status quo and future perspectives

by Bristol-Myers Squibb
  • P. Borchmann
  • P. Cramer
  1. Status quo of CAR T cell therapy for r/r DLBCL

    • P. Borchmann
  2. New perspective for the treatment of r/r CLL

    • P. Cramer
  3. CAR T – Lessons Learned

    • C. Scheid
Großer Saal


Unraveling Complex Treatment Pathways for Patients with Relapsed / Refractory Hodgkin Lymphoma

by Takeda
  • A. Sureda
  1. Welcome and introduction

    • A. Sureda
  2. Navigating Complex Treatment Decisions in R/R HL

    • T. Vasilakopoulos
  3. Challenging Case Study #1

    • M. Hutchings
  4. Learning from Real-World Evidence to Inform Treatment Decisions in R / R HL

    • A. Sureda
  5. Challenging Case Study #2

    • M. Hutchings
  6. Audience Q&A

Foyer (First Floor)


Farewell

 
Coffee Break
Coffee Break
Großer Saal


Opening and Award Ceremony

  1. Welcoming Address

    • A. Engert
  2. Award Ceremony

    • P. Borchmann
    • S. Borchmann
    • P. Bröckelmann
    • D. Eichenauer
  3. Introduction to the Keynote Lecturer

    • V. Diehl
  4. Keynote Lecture

    • U. Şahin
Großer Saal


Immunotherapy

  • P. Armand
  • P. Zinzani
  1. New findings and new challenges since last ISHL

    • S. Ansell
  2. Circulating tumor DNA in classical Hodgkin lymphoma patients treated with pembrolizumab and chemotherapy: dynamic response assessment and correlation with baseline total metabolic tumor volume

    • R. Lynch
  3. Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

    • J. Timmerman
  4. Vision Corner Stimulus Talk: The future of translational science in HL

    • C. Steidl
  5. Vision Corner Stimulus Talk: Best use of PD1 blockade in frontline treatment

    • G. Collins
  6. Vision Corner Stimulus Talk: Leveraging PD1 blockade for cure

    • P. Bröckelmann
  7. Vision Corner: Discussion

    • P. Bröckelmann
    • G. Collins
    • C. Steidl
Foyer (Ground Floor)


Poster Session

Kleiner Saal


Welcome Reception